This Investment Research Paper addresses the issue of renewable power generation in the UK and in mainland Europe, which – after the deep-seated financial crisis of 2008/09 and the ensuing recession – now has better prospects of achieving critical mass. It also considers investment perspectives.
05 Feb 2019
THE MONTHLY February 2019
Time Finance plc (TIME:LON), 45.8 | AJ Bell Plc (AJB:LON), 608 | Allergy Therapeutics plc (AGY:LON), 8.5 | Arbuthnot Banking Group PLC (ARBB:LON), 840 | Avacta Group PLC (AVCT:LON), 71.5 | Amala Foods Plc (DISH:LON), 0.1 | Burford Capital Limited (BUR:LON), 332 | City of London Investment Group PLC (CLIG:LON), 428 | DP Poland PLC (DPP:LON), 7.5 | Gateley (Holdings) Plc (GTLY:LON), 59.0 | Genedrive Plc (GDR:LON), 1.3 | Haydale PLC (HAYD:LON), 0.3 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 630 | Palace Capital plc (PCA:LON), 167 | R.E.A. Holdings plc (RE:LON), 112 | Shield Therapeutics Plc (STX:LON), 6.2 | Surface Transforms PLC (SCE:LON), 0 | Titon Holdings Plc (TON:LON), 80.0 | Volta Finance Limited (VTA:LON), 585 | Warpaint London PLC (W7L:LON), 210 | ValiRx PLC (VAL:LON), 0.2 | Tissue Regenix Group plc (LSW:STU), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
THE MONTHLY February 2019
Time Finance plc (TIME:LON), 45.8 | AJ Bell Plc (AJB:LON), 608 | Allergy Therapeutics plc (AGY:LON), 8.5 | Arbuthnot Banking Group PLC (ARBB:LON), 840 | Avacta Group PLC (AVCT:LON), 71.5 | Amala Foods Plc (DISH:LON), 0.1 | Burford Capital Limited (BUR:LON), 332 | City of London Investment Group PLC (CLIG:LON), 428 | DP Poland PLC (DPP:LON), 7.5 | Gateley (Holdings) Plc (GTLY:LON), 59.0 | Genedrive Plc (GDR:LON), 1.3 | Haydale PLC (HAYD:LON), 0.3 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 630 | Palace Capital plc (PCA:LON), 167 | R.E.A. Holdings plc (RE:LON), 112 | Shield Therapeutics Plc (STX:LON), 6.2 | Surface Transforms PLC (SCE:LON), 0 | Titon Holdings Plc (TON:LON), 80.0 | Volta Finance Limited (VTA:LON), 585 | Warpaint London PLC (W7L:LON), 210 | ValiRx PLC (VAL:LON), 0.2 | Tissue Regenix Group plc (LSW:STU), 0
- Published:
05 Feb 2019 -
Author:
Hardman & Co Research Team -
Pages:
48 -
This Investment Research Paper addresses the issue of renewable power generation in the UK and in mainland Europe, which – after the deep-seated financial crisis of 2008/09 and the ensuing recession – now has better prospects of achieving critical mass. It also considers investment perspectives.